A prime-boost immunisation regimen using recombinant BCG and Pr55(gag) virus-like particle vaccines based on HIV type 1 subtype C successfully elicits Gag-specific responses in baboons (Q45180808)

From Wikidata

Jump to navigation Jump to search

scientific article published on 9 June 2009

Language	Label	Description	Also known as
English	A prime-boost immunisation regimen using recombinant BCG and Pr55(gag) virus-like particle vaccines based on HIV type 1 subtype C successfully elicits Gag-specific responses in baboons	scientific article published on 9 June 2009

Statements

scholarly article

1 reference

Europe PubMed Central

10 December 2017

A prime-boost immunisation regimen using recombinant BCG and Pr55(gag) virus-like particle vaccines based on HIV type 1 subtype C successfully elicits Gag-specific responses in baboons (English)

1 reference

Europe PubMed Central

10 December 2017

9

1 reference

Europe PubMed Central

10 December 2017

object named as

Ann Meyers

4

0 references

object named as

Clive M Gray

8

0 references

Anna-Lise Williamson

object named as

Anna-Lise Williamson

10

0 references

Carolyn Williamson

6

object named as

Carolyn Williamson

1 reference

Europe PubMed Central

10 December 2017

3

object named as

Enid G Shephard

1 reference

Europe PubMed Central

10 December 2017

1

object named as

Gerald K Chege

1 reference

Europe PubMed Central

10 December 2017

author name string

Robin Thomas

2

1 reference

Europe PubMed Central

10 December 2017

William Bourn

5

1 reference

Europe PubMed Central

10 December 2017

James Maclean

7

1 reference

Europe PubMed Central

10 December 2017

language of work or name

0 references

publication date

9 June 2009

1 reference

Europe PubMed Central

10 December 2017

1 reference

Europe PubMed Central

10 December 2017

27

1 reference

Europe PubMed Central

10 December 2017

4857-4866

1 reference

Europe PubMed Central

10 December 2017

35

1 reference

Europe PubMed Central

10 December 2017

Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Global epidemiology of HIV.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Diversity considerations in HIV-1 vaccine selection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Current progress in the development of HIV vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Toward an AIDS vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

A review of vaccine research and development: the human immunodeficiency virus (HIV).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

HIV/AIDS vaccines: 2007.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Construction, characterization, and immunogenicity of a multigene modified vaccinia Ankara (MVA) vaccine based on HIV type 1 subtype C.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Design and preclinical evaluation of a multigene human immunodeficiency virus type 1 subtype C DNA vaccine for clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

A multigene HIV type 1 subtype C modified vaccinia Ankara (MVA) vaccine efficiently boosts immune responses to a DNA vaccine in mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Factors influencing the immune response to foreign antigen expressed in recombinant BCG vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Recombinant BCG vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Rabbits immunised with recombinant BCG expressing the cottontail rabbit papillomavirus (CRPV) L2E7E2 genes induces regression of established papillomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Heterologous boost vaccines for bacillus Calmette-Guérin prime immunization against tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Recombinant BCG vaccine candidates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Gates grant boosts tuberculosis vaccine research. US82.9 million dollars grant will double global spending on new tuberculosis vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Childhood tuberculosis: old and new vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Humoral and cell-mediated immune responses to live recombinant BCG–HIV vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Cross-clade neutralizing antibody production against human immunodeficiency virus type 1 clade E and B' strains by recombinant Mycobacterium bovis BCG-based candidate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

HIV mucosal vaccine: nasal immunization with rBCG-V3J1 induces a long term V3J1 peptide-specific neutralizing immunity in Th1- and Th2-deficient conditions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Protective immune responses induced by secretion of a chimeric soluble protein from a recombinant Mycobacterium bovis bacillus Calmette-Guérin vector candidate vaccine for human immunodeficiency virus type 1 in small animals

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Cytotoxic T lymphocyte response in mice induced by a recombinant BCG vaccination which produces an extracellular alpha antigen that fused with the human immunodeficiency virus type 1 envelope immunodominant domain in the V3 loop

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Oral recombinant Mycobacterium bovis bacillus Calmette-Guérin expressing HIV-1 antigens as a freeze-dried vaccine induces long-term, HIV-specific mucosal and systemic immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Combined intrarectal/intradermal inoculation of recombinant Mycobacterium bovis bacillus Calmette-Guérin (BCG) induces enhanced immune responses against the inserted HIV-1 V3 antigen.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Intradermal and oral immunization with recombinant Mycobacterium bovis BCG expressing the simian immunodeficiency virus Gag protein induces long-lasting, antigen-specific immune responses in guinea pigs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

A Cocktail of Mycobacterium bovis BCG Recombinants Expressing the SIV Nef, Env, and Gag Antigens Induces Antibody and Cytotoxic Responses in Mice Vaccinated by Different Mucosal Routes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Expression of heterologous genes in Mycobacterium bovis BCG: induction of a cellular response against HIV-1 Nef protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

The kinetics of specific immune responses in rhesus monkeys inoculated with live recombinant BCG expressing SIV Gag, Pol, Env, and Nef proteins.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Mucosal administration of three recombinant Mycobacterium bovis BCG-SIVmac251 strains to cynomolgus macaques induces rectal IgAs and boosts systemic cellular immune responses that are primed by intradermal vaccination.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guérin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Progress towards an HIV vaccine based on recombinant bacillus Calmette-Guérin: failures and challenges

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Improve protective efficacy of a TB DNA-HSP65 vaccine by BCG priming.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Vaccine platform for prevention of tuberculosis and mother-to-child transmission of human immunodeficiency virus type 1 through breastfeeding

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Recombinant Mycobacterium bovis bacillus Calmette-Guerin elicits human immunodeficiency virus type 1 envelope-specific T lymphocytes at mucosal sites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Analysis of HIV particle formation using transient expression of subviral constructs in mammalian cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

HIV type 1 Gag virus-like particle budding from spheroplasts of Saccharomyces cerevisiae

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Construction, expression, and immunogenicity of chimeric HIV-1 virus-like particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Safety and immunogenicity of recombinant human immunodeficiency virus-like particles in rodents and rhesus macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Priming of strong, broad, and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Virus-like particles as HIV-1 vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Recombinant HIV-1 Pr55gag virus-like particles: potent stimulators of innate and acquired immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

CD8alpha- CD11b+ dendritic cells present exogenous virus-like particles to CD8+ T cells and subsequently express CD8alpha and CD205 molecules.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

In vivo, dendritic cells can cross-present virus-like particles using an endosome-to-cytosol pathway.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Baculovirus-derived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Yeast-derived human immunodeficiency virus type 1 p55(gag) virus-like particles activate dendritic cells (DCs) and induce perforin expression in Gag-specific CD8(+) T cells by cross-presentation of DCs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Chimaeric HIV-1 subtype C Gag molecules with large in-frame C-terminal polypeptide fusions form virus-like particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Human immunodeficiency virus type 1 subtype C Gag virus-like particle boost substantially improves the immune response to a subtype C gag DNA vaccine in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

HIV-1 subtype C Pr55gag virus-like particle vaccine efficiently boosts baboons primed with a matched DNA vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Immunogenicity of HIV-1 Env and Gag in baboons using a DNA prime/protein boost regimen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Baboon as a nonhuman primate model for vaccine studies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Vaccine-induced immunity in baboons by using DNA and replication-incompetent adenovirus type 5 vectors expressing a human immunodeficiency virus type 1 gag gene

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Human immunodeficiency virus type 2 DNA vaccine provides partial protection from acute baboon infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

The immune response of the Chacma baboon to Bacille Calmette Guerin: development of a primate model for BCG-based vaccine research

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Molecular study of Mhc-DRB in wild chacma baboons reveals high variability and evidence for trans-species inheritance.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Polymorphism, haplotype composition, and selection in the Mhc-DRB of wild baboons

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Transient virus infection and pathogenesis of a new HIV type 2 isolate, UC12, in baboons

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Broad, high-magnitude and multifunctional CD4+ and CD8+ T-cell responses elicited by a DNA and modified vaccinia Ankara vaccine containing human immunodeficiency virus type 1 subtype C genes in baboons

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Characterization and selection of HIV-1 subtype C isolates for use in vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

A double-blind, placebo-controlled study of Mycobacterium-specific human immune responses induced by intradermal bacille Calmette-Guérin vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Immune responses stimulated by percutaneous and intradermal bacille Calmette-Guérin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Studies using a viral challenge and CD8 T cell depletions on the roles of cellular and humoral immunity in the control of an SHIV-89.6P challenge in DNA/MVA-vaccinated macaques.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Effect of CD8+ lymphocyte depletion on virus containment after simian immunodeficiency virus SIVmac251 challenge of live attenuated SIVmac239delta3-vaccinated rhesus macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Correlation between breadth of memory HIV-specific cytotoxic T cells, viral load and disease progression in HIV infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

T-cell epitope mapping using the ELISPOT approach

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Novel and promiscuous CTL epitopes in conserved regions of Gag targeted by individuals with early subtype C HIV type 1 infection from southern Africa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Hierarchical targeting of subtype C human immunodeficiency virus type 1 proteins by CD8+ T cells: correlation with viral load

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Preservation of functional virus-specific memory CD8+ T lymphocytes in vaccinated, simian human immunodeficiency virus-infected rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Recombinant Mycobacterium bovis BCG prime-recombinant adenovirus boost vaccination in rhesus monkeys elicits robust polyfunctional simian immunodeficiency virus-specific T-cell responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

A reduced antigen load in vivo, rather than weak inflammation, causes a substantial delay in CD8+ T cell priming against Mycobacterium bovis (bacillus Calmette-Guérin).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Reducing the stimulation of CD8+ T cells during infection with intracellular bacteria promotes differentiation primarily into a central (CD62LhighCD44high) subset

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Duration of antigen expression in vivo following DNA immunization modifies the magnitude, contraction, and secondary responses of CD8+ T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Rapid memory CD8+ T-lymphocyte induction through priming with recombinant Mycobacterium smegmatis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

DNA vaccines against human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Requirement for CD4 T Cell Help in Generating Functional CD8 T Cell Memory

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

CD8+ T cell contraction is controlled by early inflammation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

HIV-1 T-cell vaccines: evaluating the next step

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.064

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2009.05.064

1 reference

Europe PubMed Central

10 December 2017

1 reference

Europe PubMed Central

10 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45180808&oldid=2069144185"